Phosphoproteomic analysis identifies activated MET-axis PI3K/AKT and MAPK/ERK in lapatinib-resistant cancer cell line

Experimental and Molecular Medicine

Volumn 45, Issue 11, 2013, Pages

  Lee, Yong Yook ^a,b   Kim, Hwang Phill ^b   Kang, Min Jueng ^a   Cho, Byoung Kyu ^a   Han, Sae Won ^b   Kim, Tae You ^b   Yi, Eugene C ^a,b  

^a Seoul National University   (South Korea)

^b Seoul National University   (South Korea)

Author keywords

Drug resistance; HER2 positive gastric cancer; Lapatinib; Phosphoproteins; Q Exactive; Therapeutic targets

Indexed keywords

CRIZOTINIB; DACTOLISIB; LAPATINIB; LIM PROTEIN; MICROTUBULE ASSOCIATED PROTEIN 5; MITOGEN ACTIVATED PROTEIN KINASE; PALLADIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOPEPTIDE; PHOSPHOPROTEIN; PROTEIN KINASE B; SARACATINIB; SELUMETINIB; TITANIUM DIOXIDE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; MITOGEN ACTIVATED PROTEIN KINASE KINASE; QUINAZOLINE DERIVATIVE; SCATTER FACTOR RECEPTOR;

ARTICLE; CANCER CELL; CELL CYCLE ARREST; CELL PROLIFERATION; CONTROLLED STUDY; DRUG SENSITIVITY; DRUG TARGETING; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; MASS SPECTROMETER; PHOSPHOPROTEOMIC ANALYSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEOMICS; SIGNAL TRANSDUCTION; STOMACH CANCER; DRUG RESISTANCE; METABOLISM; PHOSPHORYLATION; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; HUMANS; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROTEOMICS; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-MET; QUINAZOLINES;

EID: 84892173065     PISSN: 12263613     EISSN: 20926413     Source Type: Journal    
DOI: 10.1038/emm.2013.115     Document Type: Article

References (33)

1. Monsey J, Shen W, Schlesinger P, Bose R. Her4 and Her2/neu tyrosine kinase domains dimerize and activate in a reconstituted in vitro system. J Biol Chem 2010; 285: 7035-7044.
2. Higa GM, Abraham J. Lapatinib in the treatment of breast cancer. Expert Rev Anticancer Ther 2007; 7: 1183-1192.
3. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-182.
4. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244: 707-712.
5. De Vita F, Giuliani F, Silvestris N, Catalano G, Ciardiello F, Orditura M. Human epidermal growth factor receptor 2 (HER2) in gastric cancer: A new therapeutic target. Cancer Treat Rev 2010; 36 (Suppl 3), S11-S15.
6. Rusnak DW, Lackey K, Affleck K, Wood ER, Alligood KJ, Rhodes N et al. The effects of the novel, reversible epidermal growth factor receptor/ErbB-Tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Ther 2001; 1: 85-94.
7. Cameron DA, Stein S. Drug insight: Intracellular inhibitors of HER2-clinical development of lapatinib in breast cancer. Nature clinical practice. Oncology 2008; 5: 512-520.
8. Ryan Q, Ibrahim A, Cohen MH, Johnson J, Ko CW, Sridhara R et al. FDA drug approval summary: Lapatinib in combination with capecitabine for previously treated metastatic breast cancer that overexpresses HER-2. Oncologist 2008; 13: 1114-1119.
9. Kim JW, Kim HP, Im SA, Kang S, Hur HS, Yoon YK et al. The growth inhibitory effect of lapatinib, a dual inhibitor of EGFR and HER2 tyrosine kinase, in gastric cancer cell lines. Cancer Lett 2008; 272: 296-306.
10. Kim HP, Yoon YK, Kim JW, Han SW, Hur HS, Park J et al. Lapatinib, a dual EGFR and HER2 tyrosine kinase inhibitor, downregulates thymidylate synthase by inhibiting the nuclear translocation of EGFR and HER2. PLoS One 2009; 4: E5933.
11. GlaxoSmithKline. Lapatinib optimization study in ErbB2 (HER2) positive gastric cancer: A phase III global, blinded study designed to evaluate clinical endpoints and safety of chemotherapy plus lapatinib http:// clinicaltrials.gov/ ct2/show/NCT00680901 2008
12. Nahta R, Yuan LXH, Du Y, Esteva FJ. Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: Effects on insulin-like growth factor I signaling. Mol Cancer Ther 2007; 6: 667-674.
13. Chen FL, Xia W, Spector NL. Acquired resistance to small molecule ErbB2 tyrosine kinase inhibitors. Clin Cancer Res 2008; 14: 6730-6734.
14. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007; 316: 1039-1043.
15. Yano S, Wang W, Li Q, Matsumoto K, Sakurama H, Nakamura T et al. Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-Activating mutations. Cancer Res 2008; 68: 9479-9487.
16. Chen CT, Kim H, Liska D, Gao S, Christensen JG, Weiser MR. Met activation mediates resistance to lapatinib inhibition of HER2-Amplified gastric cancer cells. Mol Cancer Ther 2012; 11: 660-669.
17. Rosenfeld J, Capdevielle J, Guillemot JC, Ferrara P. In-gel digestion of proteins for internal sequence analysis after one-or two-dimensional gel electrophoresis. Anal Biochem 1992; 203: 173-179.
18. Nesvizhskii AI, Keller A, Kolker E, Aebersold R. A statistical model for identifying proteins by tandem mass spectrometry. Anal Chem 2003; 75: 4646-4658.
19. Keller A, Nesvizhskii AI, Kolker E, Aebersold R. Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search. Anal Chem 2002; 74: 5383-5392.
20. Beausoleil SA, Villen J, Gerber SA, Rush J, Gygi SP. A probability-based approach for high-Throughput protein phosphorylation analysis and site localization. Nat Biotechnol 2006; 24: 1285-1292.
21. Lee YY, McKinney KQ, Ghosh S, Iannitti DA, Martinie JB, Caballes FR et al. Subcellular tissue proteomics of hepatocellular carcinoma for molecular signature discovery. J Proteome Res 2011; 10: 5070-5083.
22. Mayya V, Lundgren DH, Hwang SI, Rezaul K, Wu L, Eng JK et al. Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions. Sci Signal 2009; 2ra46.
23. Casado P, Cutillas PR. A self-validating quantitative mass spectrometry method for assessing the accuracy of high-content phosphoproteomic experiments. Mol Cell Proteomics 2011; 10: M110 003079.
24. Alcolea MP, Casado P, Rodriguez-Prados JC, Vanhaesebroeck B, Cutillas PR. Phosphoproteomic analysis of leukemia cells under basal and drugtreated conditions identifies markers of kinase pathway activation and mechanisms of resistance. Mol Cell Proteomics 2012; 11: 453-466.
25. Dulak AM, Gubish CT, Stabile LP, Henry C, Siegfried JM. HGF-independent potentiation of EGFR action by c-Met. Oncogene 2011; 30: 3625-3635.
26. Kulig J, Kolodziejczyk P, Kulig P, Legutko J. Targeted therapy for gastric cancer-current status. J Oncol Pharm Pract 2013; 19: 75-81.
27. Nahta R, Shabaya S, Ozbay T, Rowe DL. Personalizing HER2-Targeted therapy in metastatic breast cancer beyond HER2 status: What we have learned from clinical specimens. Curr Pharmacogenomics Person Med 2009; 7: 263-274.
28. Rexer BN, Ham AJ, Rinehart C, Hill S, Granja-Ingram Nde M, Gonzalez- Angulo AM et al. Phosphoproteomic mass spectrometry profiling links Src family kinases to escape from HER2 tyrosine kinase inhibition. Oncogene 2011; 30: 4163-4174.
29. Puri N, Salgia R. Synergism of EGFR and c-Met pathways, cross-Talk and inhibition, in non-small cell lung cancer. J Carcinog 2008; 7: 9.
30. Xu H, Stabile LP, Gubish CT, Gooding WE, Grandis JR, Siegfried JM. Dual blockade of EGFR and c-Met abrogates redundant signaling and proliferation in head and neck carcinoma cells. Clin Cancer Res 2011; 17: 4425-4438.
31. Stabile LP, Rothstein ME, Keohavong P, Lenzner D, Land SR, Gaither- Davis AL et al. Targeting of both the c-Met and EGFR pathways results in additive inhibition of lung tumorigenesis in transgenic mice. Cancers 2010; 2: 2153-2170.
32. Agarwal S, Zerillo C, Kolmakova J, Christensen JG, Harris LN, Rimm DL et al. Association of constitutively activated hepatocyte growth factor receptor (Met) with resistance to a dual EGFR/Her2 inhibitor in non-smallcell lung cancer cells. Br J Cancer 2009; 100: 941-949.
33. McDermott U, Pusapati RV, Christensen JG, Gray NS, Settleman J. Acquired resistance of non-small cell lung cancer cells to MET kinase inhibition is mediated by a switch to epidermal growth factor receptor dependency. Cancer Res 2010; 70: 1625-1634.